Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
Completed
Alexion Pharmaceuticals
Phase 2
The main purpose of the study was to evaluate the efficacy of ALXN1840 (formerly WTX101) for
24 weeks on non-ceruloplasmin-bound copper (NCC) concentrations adjusted for molybdenum
plasma concentration in participants newly diagnosed with Wilson Disease (WD) who were aged
18 and older and who had NCC concentrations within or above the reference range at the time
of enrollment in the study. The study consisted of a 24-week Treatment Period, followed by a
planned 36-month Extension Period.
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
Completed
Wilson Therapeutics AB
Phase 2
The main purpose of the study was to evaluate the efficacy of ALXN1840 (formerly WTX101) for
24 weeks on non-ceruloplasmin-bound copper (NCC) concentrations adjusted for molybdenum
plasma concentration in participants newly diagnosed with Wilson Disease (WD) who were aged
18 and older and who had NCC concentrations within or above the reference range at the time
of enrollment in the study. The study consisted of a 24-week Treatment Period, followed by a
planned 36-month Extension Period.
Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease With an Extension Period of up to 60 Months
Active, not recruiting
Alexion Pharmaceuticals
Phase 3
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101)
administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD)
participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and
safety will be evaluated during an optional 60-month Extension Period.
Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease With an Extension Period of up to 60 Months
Active, not recruiting
Wilson Therapeutics AB
Phase 3
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101)
administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD)
participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and
safety will be evaluated during an optional 60-month Extension Period.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
